• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

    10/3/23 7:00:00 AM ET
    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGBA alert in real time by email

    MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    For updates, follow us on Twitter

    Day 1

    October 4, 2023

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    AGBA Group Holding Limited (NASDAQ:AGBA)

    Mr. Wing-Fai Ng, Group President of AGBA Group

    9:40 - 10:10

    Loop Industries, Inc. (NASDAQ:LOOP)

    Kevin C. O'Dowd, VP Communications

    10:15 - 10:45

    CoTec Holdings Corp. (OTCQB:CTHCF) (TSXV:CTH)

    Julian Treger, President / CEO

    10:50 - 11:20

    ASP Isotopes, Inc. (NASDAQ:ASPI)

    Paul Elliot Mann, CEO

    11:25 - 11:55

    Akari Therapeutics, plc (NASDAQ:AKTX)

    Rachelle Jacques, CEO

    12:00 - 12:30

    FendX Technologies, Inc. (OTCQB:FDXTF) (CSE:FNDX)

    Carolyn Jane Myers, CEO

    1:10 - 1:40

    NeuroSense Therapeutics, Ltd. (NASDAQ:NRSN)

    Alon Ben-Noon, Co-Founder, CEO & Director

    Postponed to November 1, 2023

    Coeptis Therapeutics Holdings, Inc., (NASDAQ:COEP)

    David Mehalick, President / CEO

    2:55 - 3:05

    Rakovina Therapeutics Inc. (TSXV:RKV)

    Jeffrey Bacha, Executive Chairman & David Hyman, President

    3:10 - 3:20

    Alpha Tau Medical, Inc. (NASDAQ:DRTS)

    Raphi Levy, CFO

    3:25 - 3:35

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    David Dodd, Chairman, President / CEO

    3:40 - 3:50

    Renforth Resources, Inc. (OTCQB:RFHRF) (CSE:RFR)

    Nicole Brewster, President & CEO

    3:55 - 4:05

    NeuroMetrix, Inc. (NASDAQ:NURO)

    Dr. Shai Gozani, CEO & Thomas Higgins, CFO

    Day 2

    October 5, 2023

    9:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    9:40 - 10:10

    Theriva Biologics (NYSE:TOVX)

    Steven A. Shallcross, CEO / CFO

    10:15 - 10:45

    Bioxytran, Inc. (OTCQB:BIXT)

    Mike Sheikh, Executive Vice President Business Development

    10:50 - 11:20

    Inspire Veterinary Partners, Inc. (NASDAQ:IVP)

    Kimball Carr, Chairman, President & CEO

    12:00 - 12:30

    BioLargo, Inc. (OTCQB:BLGO)

    Dennis Calvert, President / CEO

    1:10 - 1:40

    Nextech3D.ai, formerly known as "Nextech AR Solutions Corp" (OTCQX:NEXCF) (CSE:NTAR) (FSE: EP2)

    Evan Gappelberg, CEO

    1:45 - 2:15

    Sokoman Minerals Corp., (OTCQB:SICNF) (TSXV:SIC)

    Timothy Froude P. Geo. CEO, Pres & Director

    2:20 - 2:50

    Knightscope, Inc. (NASDAQ:KSCP) 

    William Santana Li Chairman & CEO

    2:55 - 3:05

    Cyngn, Inc. (NASDAQ:CYN)

    Lior Tal, CEO & Director

    3:10 - 3:20

    Citizens, Inc. (NYSE:CIA)

    Gerald W. Shields, Vice Chairman / CEO, & Jeff Conklin, CFO

    3:25 - 3:35

    Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)

    Michael Martino, CEO & Director

    3:40 - 3:50

    Steppe Gold, Ltd. (OTCQX:STPGF) (TSX:STGO)

    Aneel Singh, Exec. VP & Director

    3:55 – 4:05

    Regen Biopharma, Inc. (OTC:RGBP)

    David Koos, President / CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: Conference@EmergingGrowth.com



    Primary Logo

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $AKTX
    $AMPE
    $ASPI

    CompanyDatePrice TargetRatingAnalyst
    Akari Therapeutics plc
    $AKTX
    7/20/2026$30.00Hold → Buy
    Maxim Group
    Alpha Tau Medical Ltd.
    $DRTS
    5/28/2026$15.00Overweight
    Barclays
    Akari Therapeutics plc
    $AKTX
    4/8/2026Buy → Hold
    Maxim Group
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    More analyst ratings

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Samir Rashmikant exercised 22,474 units of American Depositary Shares representing Ordinary Shares at a strike of $0.43 (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    7/17/26 6:03:07 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operations Officer Lewis Bryon Matthew disposed of 10,697 units of Citizens, decreasing direct ownership by 50% to 10,781 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    7/16/26 11:21:16 AM ET
    $CIA
    Life Insurance
    Finance

    SEC Form 3 filed by new insider Harris Jeffery Keeslar

    3 - Z Squared Inc. (0001759186) (Issuer)

    7/7/26 9:16:58 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

    - Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting - - Median overall survival of 18.2 months and median progression-free survival of 5.4 months compare favorab

    7/21/26 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    ASP Isotopes Announces Quantum Leap Energy Research Agreement with Texas A&M Engineering Experiment Station to Advance Uranium Conversion Technology

    DALLAS, July 21, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("we," "QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has signed a research agreement with the Texas A&M Engineering Experiment Station (TEES) to advance and de-risk the commercial production of high-purity uranium hexafluoride (UF6), a critical feedstock in the existing nuclear fuel enrichment supply chain. This agreement reflects the growing momentum across Texas' nuclear industry and highlights the value of collaboratio

    7/21/26 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics

    TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC

    7/21/26 7:05:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    SEC Filings

    View All

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    7/21/26 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    7/21/26 8:05:13 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Knightscope Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Knightscope, Inc. (0001600983) (Filer)

    7/20/26 7:01:12 AM ET
    $KSCP
    Telecommunications Equipment
    Telecommunications

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Akari Therapeutics upgraded by Maxim Group with a new price target

    Maxim Group upgraded Akari Therapeutics from Hold to Buy and set a new price target of $30.00

    7/20/26 8:23:24 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Alpha Tau with a new price target

    Barclays initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $15.00

    5/28/26 8:55:01 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Akari Therapeutics downgraded by Maxim Group

    Maxim Group downgraded Akari Therapeutics from Buy to Hold

    4/8/26 8:06:49 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ben-Noon Alon bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 6% to 4,534,233 units (SEC Form 4)

    4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

    6/17/26 4:30:02 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Eisenberg Or bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 20% to 1,504,050 units (SEC Form 4)

    4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)

    6/17/26 4:30:02 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Stenberg Jon bought $48,192 worth of Citizens (10,000 units at $4.82), increasing direct ownership by 3% to 327,574 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    5/26/26 10:28:12 AM ET
    $CIA
    Life Insurance
    Finance

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

    Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O. to its Scientific Advisory Board. "Dr. LoRusso is one of the most influential leaders in oncology drug development, and her appointment represents a significant addition to Aka

    7/7/26 8:55:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

    Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa

    6/25/26 11:35:00 AM ET
    $ORMP
    $DRTS
    $SCLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quantum Leap Energy Appoints Dr. Peter Fiske to Strategic Advisory Board

    DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Dr. Peter S. Fiske to QLE's Strategic Advisory Board (SAB). "QLE is intentionally building the leadership, advisory depth, and execution discipline required to scale throughout government and commercial nuclear energy markets," said Dr. Ryno Pretorius, Chief Executive Officer of QLE. "Dr. Fiske brings firsthand experience from the highest levels of government en

    5/6/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Financials

    Live finance-specific insights

    View All

    Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

    - Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment - - One associated grade 3 serious adverse event (SAE) was observed, since resolved - - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months - - Conference call with principal investigator to be held today, Monday, May 11, 2026, at 8:30am ET - JERUSALEM, May 11, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or t

    5/11/26 7:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

    JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial. Conference Call and Webcast Details Date: Monday, May 11, 2026Time: 8:30am ETWeb Access: https://alpha-tau-interim-results-conference-call.open-exchange.net/

    5/8/26 9:10:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Cyngn Announces Date for First Quarter 2026 Financial Results

    MOUNTAIN VIEW, Calif., May 6, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) will announce its first quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 13, 2026, after the close of market. The financial results will be available on the Cyngn website under "News & Events" at https://investors.cyngn.com/.  The Company will not host an earnings call.About CyngnCyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges facing industrial orga

    5/6/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care